Joseph H. Golec

University of Connecticut - Department of Finance

School of Business

2100 Hillside Road

Storrs, CT 06269

United States

SCHOLARLY PAPERS

30

DOWNLOADS
Rank 14,084

SSRN RANKINGS

Top 14,084

in Total Papers Downloads

6,349

SSRN CITATIONS
Rank 22,214

SSRN RANKINGS

Top 22,214

in Total Papers Citations

30

CROSSREF CITATIONS

24

Scholarly Papers (30)

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

Number of pages: 38 Posted: 27 Sep 2006
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 857 (50,472)
Citation 1

Abstract:

Loading...

Pharmaceutical, Price Regulation; Profitability; Research and Development

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

NBER Working Paper No. w12676
Number of pages: 37 Posted: 20 Nov 2006 Last Revised: 20 Feb 2022
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 114 (429,253)

Abstract:

Loading...

2.

Do Investors See Through Mistakes in Reported Earnings?

Journal of Financial and Quantitative Analysis (JFQA), Forthcoming
Number of pages: 50 Posted: 13 Feb 2008 Last Revised: 06 Oct 2010
Katsiaryna Bardos, Joseph H. Golec and John P. Harding
Fairfield University, University of Connecticut - Department of Finance and University of Connecticut - School of Business - Center for Real Estate and Urban Economic Studies
Downloads 719 (64,725)
Citation 5

Abstract:

Loading...

restatements, earnings, valuation, long-run event study, corporate misreporting, valuation

3.

Litigation Risk and Market Reaction to Restatements

Journal of Financial Research, Vol. 36, No. 1, 2013
Number of pages: 45 Posted: 14 Nov 2009 Last Revised: 28 Mar 2013
Katsiaryna Bardos, Joseph H. Golec and John P. Harding
Fairfield University, University of Connecticut - Department of Finance and University of Connecticut - School of Business - Center for Real Estate and Urban Economic Studies
Downloads 460 (112,749)
Citation 1

Abstract:

Loading...

4.

Do Firms Purposefully Change Capital Structure?: Evidence from a Growth Shock to Pharmaceutical Firms

Number of pages: 54 Posted: 16 Oct 2012 Last Revised: 21 Apr 2018
Syracuse University - Whitman School of Management - Finance Department; James D. Kuhn Center for Real Estate, University of Connecticut - Department of Finance and SKEMA Business School
Downloads 409 (129,366)
Citation 3

Abstract:

Loading...

Growth prospects, growth opportunities, unsecured debt, short-term debt, debt maturity, convertible debt, leverage, debt composition, debt structure

5.

Pharmaceutical R&D Spending and Threats of Price Regulation

Number of pages: 46 Posted: 18 Mar 2008
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut- Finance Department and University of North Carolina (UNC) at Chapel Hill
Downloads 365 (147,000)
Citation 9

Abstract:

Loading...

Research and Development, Pharmaceuticals, Price Controls

6.

Incentive Fees and Mutual Fund Volatility Timing

Number of pages: 46 Posted: 13 Oct 2005 Last Revised: 05 Aug 2008
Erasmo Giambona and Joseph H. Golec
Syracuse University - Whitman School of Management - Finance Department; James D. Kuhn Center for Real Estate and University of Connecticut - Department of Finance
Downloads 363 (147,900)
Citation 3

Abstract:

Loading...

mutual fund, volatility timing, incentive fee

Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending

Number of pages: 52 Posted: 18 Mar 2005
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut- Finance Department and University of North Carolina (UNC) at Chapel Hill
Downloads 216 (250,334)

Abstract:

Loading...

Research and Development, Real Options, Price Regulation, Pharmaceutical, Biotechnology

Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending

NBER Working Paper No. w11229
Number of pages: 54 Posted: 20 Nov 2006 Last Revised: 08 Sep 2022
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut- Finance Department and University of North Carolina (UNC) at Chapel Hill
Downloads 73 (576,851)
Citation 1

Abstract:

Loading...

8.

Exploration of Potential Economics of Follow-On Biologics and Implications for Data Exclusivity Periods for Biologics

Number of pages: 19 Posted: 08 May 2009 Last Revised: 06 Nov 2012
John A. Vernon, A. Bennett and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill, affiliation not provided to SSRN and University of Connecticut - Department of Finance
Downloads 273 (199,949)

Abstract:

Loading...

9.

Informed Options Trading Before Fda Drug Advisory Committee Meetings

University of Miami Business School Research Paper No. 3825062
Number of pages: 54 Posted: 13 Apr 2021
Zekun Wu, Paul Borochin and Joseph H. Golec
Capital One Financial Corporation, University of Florida - Department of Finance, Insurance and Real Estate and University of Connecticut - Department of Finance
Downloads 269 (202,936)

Abstract:

Loading...

FDA; Informed Trading; Options;

10.

Using Options to Measure the Full Value-Effect of an Event: Application to Obamacare

Journal of Financial Economics (JFE), Forthcoming
Number of pages: 69 Posted: 05 Sep 2013 Last Revised: 08 Jul 2015
Paul Borochin and Joseph H. Golec
University of Florida - Department of Finance, Insurance and Real Estate and University of Connecticut - Department of Finance
Downloads 252 (216,541)
Citation 7

Abstract:

Loading...

Event study, options, valuation, healthcare reform

11.

Fda New Drug Approval Times, Prescription Drug User Fees, and R&D Spending

AEI-Brookings Joint Center Working Paper No. 06-21
Number of pages: 22 Posted: 20 Sep 2006
University of Connecticut - Department of Finance, University of North Carolina (UNC) at Chapel Hill, American Enterprise Institute (AEI) and U.S. Department of Health & Human Services
Downloads 242 (225,336)
Citation 2

Abstract:

Loading...

FDA, R&D, pharmaceutical

12.

Financial Risk in the Biotechnology Industry

NBER Working Paper No. w13604
Number of pages: 26 Posted: 14 Nov 2007 Last Revised: 04 Sep 2022
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 227 (239,681)

Abstract:

Loading...

Are the Insider Trades of a Large Institutional Investor Informed?

Number of pages: 44 Posted: 19 Oct 2005
Joseph H. Golec
University of Connecticut - Department of Finance
Downloads 187 (285,809)

Abstract:

Loading...

Institutional Investor, Insider, Trades

Are the Insider Trades of a Large Institutional Investor Informed?

Financial Review, Vol. 42, No. 2, May 2007
Posted: 26 Apr 2007
Joseph H. Golec
University of Connecticut - Department of Finance

Abstract:

Loading...

institutional insider, informed trades, Fidelity, mutual fund, incentive fees

14.

Strategic Trading in the Wrong Direction By a Large Institutional Insider

Number of pages: 60 Posted: 14 Jun 2006 Last Revised: 01 Sep 2009
Joseph H. Golec and Erasmo Giambona
University of Connecticut - Department of Finance and Syracuse University - Whitman School of Management - Finance Department; James D. Kuhn Center for Real Estate
Downloads 170 (311,351)

Abstract:

Loading...

Strategic Trading, Manipulation, Institutional Investor, Insider

15.

Economic Evaluation and Comparative-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation

Number of pages: 22 Posted: 24 Apr 2009
John A. Vernon and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill and University of Connecticut - Department of Finance
Downloads 165 (319,461)

Abstract:

Loading...

16.

Comparative Effectiveness Research (CER) Policies and the Potential Threat to Pharmaceutical Innovation

Number of pages: 23 Posted: 28 Mar 2010
John A. Vernon, Joseph H. Golec and Stedman Stevens
University of North Carolina (UNC) at Chapel Hill, University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 161 (326,158)

Abstract:

Loading...

Comparative Effectiveness Research, Pharmaceutical Research and Development, Pharmaceutical Regulation, Food and Drug Administration

17.

Does Earnings Management Relieve the Negative Effects of Mandatory Pension Contributions?

Financial Management, Forthcoming
Number of pages: 67 Posted: 16 Apr 2014 Last Revised: 24 Mar 2016
Hieu V. Phan, Hinh Khieu and Joseph H. Golec
University of Massachusetts Lowell, Prairie View A&M University and University of Connecticut - Department of Finance
Downloads 142 (361,592)

Abstract:

Loading...

earnings management; financial constraint; mandatory pension contribution; financing; investment

18.

Conflicts of Interest on Expert Committees: The Case of FDA Drug Advisory Committees

University of Connecticut School of Business Research Paper No. 17-02, George Mason Law & Economics Research Paper No. 18-10
Number of pages: 36 Posted: 04 Apr 2017 Last Revised: 27 Apr 2018
James C. Cooper and Joseph H. Golec
George Mason University - Antonin Scalia Law School and University of Connecticut - Department of Finance
Downloads 139 (367,684)
Citation 3

Abstract:

Loading...

Conflicts of Interest, Expert Committees, FDA, pharmaceuticals

19.

Data Exclusivity Period Length and Federal Government Savings from Enactment of the Biologics Price Competition and Innovation Act of 2007

Posted: 26 Jan 2009
Ted Buckley, Joseph H. Golec and John A. Vernon
affiliation not provided to SSRN, University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 132 (382,549)

Abstract:

Loading...

R&D, Follow-on Biologics, Data Exclusivity, R&D

What's the 'Interest' in FDA Drug Advisory Committee Conflicts of Interest?

Number of pages: 25 Posted: 25 Apr 2009
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 75 (567,670)

Abstract:

Loading...

FDA Advisory Committee Meetings, Conflicts of Interest, Stock Returns, Event Studies

What's the "Interest" in Fda Drug Advisory Committee Conflicts of Interest?

NBER Working Paper No. w14932
Number of pages: 22 Posted: 03 May 2009 Last Revised: 26 Oct 2022
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 23 (913,496)

Abstract:

Loading...

21.

Do Investors Use Customer Metrics to Value High Growth Service Firms?

The International Journal of Business and Finance Research, Vol. 6, No. 2, pp. 1-19, 2012
Number of pages: 19 Posted: 05 Jan 2012
Neeraj Gupta and Joseph H. Golec
affiliation not provided to SSRN and University of Connecticut - Department of Finance
Downloads 95 (485,730)

Abstract:

Loading...

customers, valuation, intangibles

22.

Why Does the FDA Overrule Its Expert Committees’ Recommendations?

University of Connecticut School of Business Research Paper No. 19-15
Number of pages: 32 Posted: 22 Jul 2019 Last Revised: 09 Sep 2021
Joseph H. Golec and James C. Cooper
University of Connecticut - Department of Finance and George Mason University - Antonin Scalia Law School
Downloads 78 (548,110)

Abstract:

Loading...

FDA, Drug Advisory Committees, Drug Approval Process, Drug Regulation

23.

A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics

Posted: 01 Apr 2009
John A. Vernon and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill and University of Connecticut - Department of Finance
Downloads 75 (560,409)

Abstract:

Loading...

Follow on Biologics, Data Exclusivity, Biotech Financial Risk

24.

How Excluding Some Benefits from Value Assessment of New Drugs Impacts Innovation

Number of pages: 35 Posted: 22 May 2015 Last Revised: 15 Jul 2016
Joseph Cook and Joseph H. Golec
Pfizer, Inc. and University of Connecticut - Department of Finance
Downloads 68 (591,216)
Citation 1

Abstract:

Loading...

Biopharmaceuticals, cost effectiveness, options

25.

Debt Capacity of Real Estate Collateral

Real Estate Economics, Forthcoming
Posted: 07 Feb 2013
Erasmo Giambona, Joseph H. Golec and Armin Schwienbacher
Syracuse University - Whitman School of Management - Finance Department; James D. Kuhn Center for Real Estate, University of Connecticut - Department of Finance and SKEMA Business School

Abstract:

Loading...

land & building, machinery & equipment, leverage, credit constraints

26.

The Conditional Performance of REIT Stock Repurchases

Journal of Real Estate Finance and Economics, Vol. 32, No. 2, 2006
Posted: 09 Sep 2005
Joseph H. Golec, Erasmo Giambona and Carmelo Giaccotto
University of Connecticut - Department of Finance, Syracuse University - Whitman School of Management - Finance Department; James D. Kuhn Center for Real Estate and University of Connecticut - Department of Finance

Abstract:

Loading...

REITs, Conditional Performance, Noisy Rational Expectations, Stock Repurchases

27.

Regulation and the Rise in Asset-Based Mutual Fund Management Fees

Posted: 28 Mar 2002
Joseph H. Golec
University of Connecticut - Department of Finance

Abstract:

Loading...

28.

Bettors Love Skewness, Not Risk, at the Horse Track

Journal of Political Economy Vol 106, No 1, February 1998
Posted: 11 Feb 1998
Joseph H. Golec and Maurry Tamarkin
University of Connecticut - Department of Finance and Clark University

Abstract:

Loading...

29.

Herding on Noise: The Case of Johnson Redbook's Weekly Retail Sales Data

J. OF FINANCIAL AND QUANTITATIVE ANALYSIS, Sept. 1997
Posted: 05 Nov 1997
Joseph H. Golec
University of Connecticut - Department of Finance

Abstract:

Loading...

30.

The Effects of Mutual Fund Managers' Characteristics on Their Portfolio Performance, Risk and Fees

FINANCIAL SERVICES REVIEW
Posted: 19 Mar 1997
Joseph H. Golec
University of Connecticut - Department of Finance

Abstract:

Loading...